Cargando…

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

BACKGROUND: MI-319 is a synthetic small molecule designed to target the MDM2-P53 interaction. It is closely related to MDM2 antagonists MI-219 and Nutlin-3 in terms of the expected working mechanisms. The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohammad, Ramzi M, Wu, Jack, Azmi, Asfar S, Aboukameel, Amro, Sosin, Angela, Wu, Sherwin, Yang, Dajun, Wang, Shaomeng, Al-Katib, Ayad M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794250/ https://www.ncbi.nlm.nih.gov/pubmed/19958544 http://dx.doi.org/10.1186/1476-4598-8-115

Ejemplares similares

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X(L )and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
por: Arnold, Alan A, et al.
Publicado: (2008)

SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
por: Al-Katib, Ayad M, et al.
Publicado: (2009)

I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma
por: Al-Katib, Ayad, et al.
Publicado: (2010)

MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy
por: Azmi, Asfar S., et al.
Publicado: (2010)

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
por: Muqbil, Irfana, et al.
Publicado: (2019)

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)

New targets for the treatment of follicular lymphoma
por: Tageja, Nishant, et al.
Publicado: (2009)

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
por: Sosin, Angela M, et al.
Publicado: (2012)

PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma
por: Khan, Husain Yar, et al.
Publicado: (2021)

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer
por: Gao, Jiankun, et al.
Publicado: (2014)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
por: Khan, Husain Yar, et al.
Publicado: (2019)

Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies
por: Al-Katib, Ayad M, et al.
Publicado: (2014)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective
por: Zhao, Yujun, et al.
Publicado: (2014)

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells
por: Chen, Haibo, et al.
Publicado: (2017)

Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment
por: Bao, Bin, et al.
Publicado: (2012)

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors
por: Azmi, Asfar S., et al.
Publicado: (2011)

319 Bronchial Hyperresponsiveness in Obese Adolescents
por: Ramírez, Gabriela, et al.
Publicado: (2012)

Health Tract, No. 319: Poverty and Longevity
Publicado: (1868)

Overexpression of Solanum habrochaites microRNA319d (sha-miR319d) confers chilling and heat stress tolerance in tomato (S. lycopersicum)
por: Shi, Xiaopu, et al.
Publicado: (2019)

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
por: Mpilla, Gabriel, et al.
Publicado: (2019)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
por: Masood, Ashiq, et al.
Publicado: (2011)

Nuclear Export Inhibition for Pancreatic Cancer Therapy
por: Muqbil, Irfana, et al.
Publicado: (2018)

Fungal Planet description sheets: 281–319
por: Crous, P.W., et al.
Publicado: (2014)

SAT319 Megestrol-induced Adrenal Insufficiency
por: Alcorn, Chris, et al.
Publicado: (2023)

Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth
por: Khan, Husain Yar, et al.
Publicado: (2020)

MDM2 Antagonists Counteract Drug-Induced DNA Damage
por: Vilgelm, Anna E., et al.
Publicado: (2017)

E2F1-Dependent Oncogenic Addiction of Melanoma Cells to MDM2
por: Verhaegen, Monique, et al.
Publicado: (2011)

Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
por: Sexton, Rachel, et al.
Publicado: (2019)

Network insights on oxaliplatin anti-cancer mechanisms
por: Alian, Osama M, et al.
Publicado: (2012)

Synthesis of Amino Acids Bearing Halodifluoromethyl Moieties and Their Application to p53-Derived Peptides Binding to Mdm2/Mdm4
por: Vaas, Sebastian, et al.
Publicado: (2023)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

MiR319 mediated salt tolerance by ethylene
por: Liu, Yanrong, et al.
Publicado: (2019)

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy
por: Khan, Husain Yar, et al.
Publicado: (2022)

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
por: Khan, Husain Yar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iievd4cpherg64oe4vih3etqqo